Leadership

Operational Management

Berend Oosterhuis

Chief Operations Officer

Berend

Mr. Oosterhuis holds a Master’s Degree in Biotechnology from the Wageningen University and Research Centre in The Netherlands. After graduating, Mr. Oosterhuis began his career at SOLVO in 2005 as a scientist in the Research and Development Laboratory, where he worked on the interaction of ABC transporters with environmental toxicants and neutraceutical compounds. From 2008 to 2009 he was head of SOLVO’s Contract Research Laboratory. From 2010 to 2015 Mr Oosterhuis served as Director/VP of Business Development. During that time he set up SOLVO’s sales teams in the US, Europe and Asia. He was also responsible for the publication of SOLVO’s Transporter Book and the organization of SOLVO’s Transporter Conferences. In 2016 he was promoted to COO.

Krisztina Herédi-Szabó

Principal Scientist, ADME-Tox Services

HSZK

Krisztina Herédi-Szabó, PharmD, PhD, has a degree in Pharmacy from the University of Szeged, Hungary. She has earned her PhD in the field of peptide chemistry and cell biology at Creighton University, Omaha, Nebraska, USA in 2005. She has joined Solvo Biotechnology in 2006 and started working in the field of transporter proteins. She was involved in the development of several transporter assays that are now available as products and services. She is an author of 21 scientific publications and presented her group’s work at several international conferences. Her current position is Principal Scientist, ADME-Tox Services at Solvo Biotechnology, Szeged, Hungary.

Emese Kis

Director of R&D and Production

Mesi

Dr. Kis received a Master’s Degree in Biotechnology from University of Technology and Economics of Budapest, and her Ph.D. in Biochemistry from University of Szeged. She began her career at SOLVO in 2003 as a scientist in the Research and Development Laboratory. Her focus was on development of various membrane transporter assays and she was involved in a number of scientific grants and international collaborations. From 2012 she became the Head of Production Laboratory, being responsible for cell membrane preparations and assay development and beside it she took over the operational management of the R&D department in 2016. Dr. Kis has contributed 19 peer reviewed scientific papers.

Zoltán Tímár

Head of the Bioanalytical Laboratory

Zoli

Zoltán Timár graduated with a degree in organic chemistry from Szeged (1995). As a result of academic pre- and postdoctoral research in the UK (Bristol University, 1998-1999), France (École Nationale Superieure de Chimie de Paris, 2000), and in the US (University of Colorado at Boulder, 2004-2005) in medicinal chemistry, applying synthetic organic and analytical chemistry techniques, Dr Tímár has authored numerous publications, as well as filed and issued patent applications. During this period Dr. Timár developed an interest in commercializing scientific research methods and products, and in 2007 joined the Nucleic Acid Solutions Division of Agilent Technologies in Boulder, Colorado as an expert scientist. This provided the opportunity to immerse in the fields of analytical sciences, GxP quality and commercialization of intellectual property, and resulted in the worldwide commercialization of chemical compounds for use in ribonucleic acid automated synthesis, as well as the development of several methodologies to utilize TC-RNA phosphoramidites to synthesize natural and modified short- and long-chain RNA molecules. Dr. Timár also developed analytical methodologies and software to analyze the identity, purity and sequence of oligonucleotides still currently being used for analytical services by Agilent. The change from organic synthesis to analytical chemistry, and then to business was of key importance for Dr. Timár’s career, and in 2012 he was hired by Solvo Biotechnology as Head of the Bioanalytical Laboratory, leading a team of five scientists, and overseeing several hundred successful HPLC-MS/MS method developments. Under his leadership, Solvo analytical services strives to continuously develop by providing up-to-date training for employees, applying best laboratory practices and instrumentation, and aiming to be a top quality, highly productive and dependable provider for Solvo customers all over the world. Dr. Timár holds a PhD. (summa cum laude) in Organic Chemistry, awarded by Szeged University in 2000.

Joe Zolnerciks

Vice President of Business Development

Joe

Joe Zolnerciks has extensive experience working in the field of drug transporters and membrane protein biochemistry. After receiving a B.Sc. in Medical Molecular Biology from Cardiff University and M.Res. in Integrative Biomedical Sciences from Imperial College London, he was awarded his Ph.D. in Biochemistry for the study of ATP-binding cassette (ABC) transporter structure and function in the laboratory of Dr Christopher Higgins and Dr Kenneth Linton at Imperial College London. This was followed by postdoctoral fellowships in the Departments of Pharmaceutics and Medicinal Chemistry at the University of Washington, and the Blizard Institute, Queen Mary University of London, as well as a Federation of European Biochemical Societies (FEBS) Short-Term Fellowship at the Biozentrum, University of Basel. During this time, his research focused on the biochemistry of ABC transporters, transporter-mediated drug-drug interactions and toxicity, and the role of transporters in pharmacokinetics. Dr Zolnerciks first joined SOLVO Biotechnology in 2012 as Head of Production at one of their main lab sites in Szeged, Hungary, where he was responsible for overseeing product development and manufacture, as well as leading improvements in bioprocess development. As a result of subsequent robust growth in the North American market, he joined SOLVO USA, Inc. in 2014 as Director of ADME-Tox Services, and opened SOLVO’s West Coast US office in Seattle, WA. In addition to providing technical and scientific consultation services for SOLVO’s client base, Dr Zolnerciks has been increasingly involved in business development and sales activities, initially managing the North American sales team before being promoted to his current position. He is the author of over 30 research papers, reviews, book chapters, and presentations in the field of drug transporters and drug-induced toxicity.

Kitti Zsák Péterné Szabó

Director of Operational Support

Kitti

Kitti Zsák Péterné Szabó graduated as a Biochemical Engineer (MSc) and completed Quality Assurance Special Studies at the Budapest University of Technology and Economics. She started her career at SOLVO Biotechnology in 2008 as a scientist in the Research and Development Laboratory where she worked on the species specificity profiling of rat and human organic cation/carnitine transporter Slc22a5/SLC22A5 (Octn2/OCTN2). She is a certified ISO 9001 Internal Auditor and Quality Assurance Manager and she is qualified in ISO/IEC 17025 Document Management and GLP. She has joined the Quality Assurance Unit in 2013 and she became the Head of the Quality Assurance Unit in 2014.

Executive Management

Ernő Duda

Founder, President & CEO

Ernő

Also Founder and President of the Hungarian Biotechnology Association, a representative organization active in lobbying for the interests of its member companies and the biotechnology sector in Hungary. As a genuine entrepreneur, he has founded or co-founded 13 companies over the past 15 years, including a corporate finance consulting company focused on high-tech Hungarian start-ups, and Hungary's largest online second-hand book store. He was Vice president of the American Chamber of Commerce in Hungary for 2 years, and President of the Junior Achievement Foundation Hungary from 1997 until 2006. Mr. Duda is a member of the Board of the Hungarian Association for Innovation. Besides running a course at the University of Szeged, he regularly holds presentations at conferences and various public events. He has been awarded the Order of Merit of the Republic of Hungary for his distinguished contribution to the development of the Hungarian biotechnology industry.

Berend Oosterhuis

Chief Operations Officer

Berend

Mr. Oosterhuis began his career at SOLVO in 2005 as a scientist in the Research and Development Laboratory, where he worked on the interaction of ABC transporters with environmental toxicants and neutraceutical compounds. He also worked on the development of various transporter assays and was involved in a number of scientific collaborations. Before promoted to BD Director, he served as the Head of the Service Laboratory, and gained valuable knowledge about the ADME-Tox field and the role of transporter proteins in it. In January 2010 he became responsible for all of SOLVO’s customer related activities, including Sales, Marketing and Business Development, but also the company’s Contract Research activities. In this role he oversaw customer interactions from the first inquiry until the final report being sent out to customers. As a result of the continuous growth of the company, a VP for Global operations was hired as well as a senior director for US Business Development and Operations in 2012. As a result of this, Mr Oosterhuis was promoted to VP of Business Development. Mr. Oosterhuis holds a Master’s Degree in Biotechnology from the Wageningen University and Research Centre.

Péter Krajcsi, Ph.D.

Chief Scientific Officer

Péter

Before joining SOLVO Biotechnology in 2002, he worked as Director of Biology at ComGenex Inc., Budapest, Hungary. He was Senior Scientist of VirRx LLC, St. Louis, MO, USA between 2000 and 2001, and worked as Head of the Department of Molecular Cell Biology and Biochemistry at Biorex R&D Co. Hungary between 1998 and 1999. Before 1998, he had held various academic positions in Hungary and in the United States, including the position of Visiting Scientist at Northwestern University, Dept. of Pathology, Chicago, IL, USA and Visiting Research Associate at the Inst. for Molecular Virology and Dept. of Molecular Microbiology and Immunology, St. Louis University Medical School, St. Louis, MO, USA. Dr. Krajcsi has a Ph.D. in Molecular Cell Biology and in Biochemistry and received a Doctor of Sciences (DSc) degree from the Hungarian Academy of Sciences. He has published over 80 articles in peer-reviewed scientific journals. He is a Scientific Advisor at the Dept. of Morphology and Physiology, Faculty of Health Sciences, Semmelweis University, Budapest.

Szabolcs Hajdú

Chief Financial Officer

Szabolcs

Before joining SOLVO Biotechnology in 2008, Mr. Hajdú worked as Financial Director of Főszer-Electric Zrt. (2001-2008), where his responsibilities included managing IT, logistics and various finance activities such as the development of liquidity management; development and improvement of controlling organization; project management of significant multinational projects; coordination of internal development and investment areas; management of tenders; representation of the company in professional organisations; coordination of activities of affiliates; and the development of professional trainings. Mr. Hajdú holds degrees as Programmer Mathematician, as Economist and Accountant, and as Economist in specialization of Enterprise Development.

Board of Directors

Dr Jean-François Le Bigot

Dr Jean-François Le Bigot is the chairman and CEO of Citoxlab Group one of the leading international non-clinical Contract Research Organisation (CRO). With 39 years’ experience in drug development, he manages 8 research sites located in 5 countries which provide a comprehensive range of pre-clinical services and specialty safety evaluation services to meet the needs of pharmaceutical, biotechnology and chemical companies worldwide.

After gaining a PhD in Biochemical Pharmacology (Université Pierre et Marie Curie, Paris, 1979), Jean-Francois Le Bigot joined Sandoz Laboratories (Novartis now) as Head of experimental biology and then Director of Pre-Clinical Development in France. He joined CIT (Centre International de Toxicologie) in 1987 as Director of Toxicology and became CEO of the company in 1992. After a first investment in Atlanbio, a CRO specializing in bioanalysis, he orchestrated the acquisition of LAB-Research Group (with facilities in Canada, Denmark and Hungary) in 2011 and became the Chairman and CEO of Citoxlab Group. Citoxlab acquired more recently Accellab (Montreal), a CRO specialized in medical devices (2016), Xenometrics (Kansas-City, 2017) and Solvo (Budapest) the leader in transport and DDI studies (2018). 
As a consequence of the development of activities, CIT then Citoxlab staff increased from 140 to 1300 between 1987 and 2018.

Patrick Spies

Patrick Spies holds a Master in corporate law from the Paris II University and a Parisian Political Science School Diploma in economics and finance.He started his professional career as a financial auditor with Arthur Andersen in Paris. Then he became Deputy Director of the Joire Pajot Martin Bank (Bearbull Group), General Services and Non-strategic Buying Director for the Hachette Filipacchi Médias Group, General Director in charge of administration and finance with SEP (Walter Marketing Group), and General Secretary of the Beauvallet Group.

He is currently Executive Vice President – General Secretary and Corporate Development for the CiToxLAB Group. The Group offers a wide range of preclinical services in response to the requirements of pharmaceutical, chemical and biotechnology companies around the world. Citoxlab performs general and reproductive toxicology, carcinogenesis, bioanalysis, immunology and safety pharmacology studies, and was formed in 2011 by the fusion of CIT and LAB-Research. The Citoxlab Group employs more than 1,300 people over eight sites (two in France, two in Canada, one in Denmark, two in Hungary and one in the USA).

Christopher Banks

Chris Banks is a Diplomat of the American Board of Toxicology. His career has spanned three decades in contract research. He worked for 12 years with LSR in the UK, prior to spending 19 years in Canada with Charles River Laboratories (formerly CTBR and Bio-Research). His roles have included Scientific Director of Inhalation Toxicology, Director of Scientific Operations and Director of Project Management, responsible for the oversight and coordination of drug development programs for current or future key clients. He joined Citoxlab, Hungary as the Managing Director in January 2008 and left in 2014 to pursue other activities, but remained an active member of the Board of Directors for Hungary and a member of the Scientific Advisory Board for the Citoxlab Group. Chris re-joined the Citoxlab Group at the end of 2017 as the Senior Vice President of Business Development, EMEA and Global Director of Inhalation Toxicology.

Ernő Duda

Founder and CEO, SOLVO Biotechnology Also Founder and President of the Hungarian Biotechnology Association, a representative organization active in lobbying for the interests of its member companies and the biotechnology sector in Hungary. As a genuine entrepreneur, he has founded or co-founded 13 companies over the past 15 years, including Copy General, a corporate finance consulting company focused on high-tech Hungarian start-ups, and Hungary's largest online second-hand book store. He was Vice President of the American Chamber of Commerce in Hungary for 2 years, and President of the Junior Achievement Foundation Hungary from 1997 until 2006. Mr. Duda is a member of the Research and Technology Innovation Council of the National Office for Research and Technology, the Board of Trustees of the Bay Zoltán Foundation for Applied Research, and the Board of the Hungarian Association for Innovation. His course 'Biotechnology from a Business Perspective' has been running at the University of Szeged since 2004. He has been awarded the Order of Merit of the Republic of Hungary for his distinguished contribution to the development of the Hungarian biotechnology industry.

Berend Oosterhuis

Mr. Oosterhuis began his career at SOLVO in 2005 as a scientist in the Research and Development Laboratory, where he worked on the interaction of ABC transporters with environmental toxicants and neutraceutical compounds. He also worked on the development of various transporter assays and was involved in a number of scientific collaborations. Before promoted to BD Director, he served as the Head of the Service Laboratory, and gained valuable knowledge about the ADME-Tox field and the role of transporter proteins in it. In January 2010 he became responsible for all of SOLVO’s customer related activities, including Sales, Marketing and Business Development, but also the company’s Contract Research activities. In this role he oversaw customer interactions from the first inquiry until the final report being sent out to customers. As a result of the continuous growth of the company, a VP for Global operations was hired as well as a senior director for US Business Development and Operations in 2012. As a result of this, Mr Oosterhuis was promoted to VP of Business Development. Mr. Oosterhuis holds a Master’s Degree in Biotechnology from the Wageningen University and Research Centre.